Schedule 13D ownership disclosure
ARS Pharmaceuticals Inc
Common Stock, par value $0.0001 per share · CUSIP: 82835W108
Event date: 2025-09-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 10,940,977.00 · Class: 11.1%
- Peter KolchinskyReported CIK 0001384859
Shares: 10,940,977.00 · Class: 11.1%
- Rajeev ShahReported CIK 0001619841
Shares: 10,940,977.00 · Class: 11.1%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 9,958,073.00 · Class: 10.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-25-000011
- Form type
- SCHEDULE 13D/A
- Filer
- ARS Pharmaceuticals, Inc.
- CIK
- CIK 1671858
- Filed
- Oct 01, 2025
- Reporting period
- Sep 29, 2025
- Description
- Schedule 13D beneficial ownership